STOCK TITAN

Viking Therapeutics, Inc - $VKTX STOCK NEWS

Welcome to our dedicated page for Viking Therapeutics news (Ticker: $VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viking Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viking Therapeutics's position in the market.

Rhea-AI Summary
Viking Therapeutics, a clinical-stage biopharmaceutical company, will participate in several upcoming investor conferences. The Truist Securities 2023 BioPharma Symposium and UBS 2023 BioPharma Conference will include 1-on-1 meetings, while the Stifel 2023 Healthcare Conference will feature a corporate presentation by Brian Lian, Viking's CEO. Dr. Lian will also deliver a corporate presentation at the Jefferies 2023 London Healthcare Conference and participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
conferences
-
Rhea-AI Summary
Viking Therapeutics announces financial results for Q3 2023 and provides pipeline update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.42%
Tags
-
Rhea-AI Summary
Viking Therapeutics completes patient enrollment in Phase 2 clinical trial of VK2735, a potential treatment for metabolic disorders. Trial size increased to 176 patients due to high demand. Results expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
Rhea-AI Summary
Viking Therapeutics to release financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences earnings
-
Rhea-AI Summary
Viking Therapeutics announces new results from Phase 1 trial of VK2735 for metabolic disorders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary
Viking Therapeutics to present data on VK2735 at ObesityWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
Rhea-AI Summary
Viking Therapeutics to participate in two upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
conferences
-
Rhea-AI Summary
Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, a dual agonist of GLP-1 and GIP receptors, for the potential treatment of metabolic disorders such as obesity. The 13-week trial will evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of four different doses of VK2735. The primary endpoint is the percent change in body weight from baseline to Week 13.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
Rhea-AI Summary
Viking Therapeutics, Inc. will release its financial results for the second quarter of 2023 on July 26. The company, focused on developing therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time to discuss the results and general corporate updates. A telephone replay will be available until August 2, and the conference call can also be accessed live via the internet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences earnings
Viking Therapeutics, Inc

Nasdaq:VKTX

VKTX Rankings

VKTX Stock Data

8.49B
95.04M
5.49%
72%
8.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About VKTX

novel therapeutics for metabolic and endocrine disorders.